Product logins

Find logins to all Clarivate products below.


Dementia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence of dementia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s dementia forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dementia and the number of new diagnoses of dementia?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dementia over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following dementia subpopulations:

  • Top-line epidemiology: Total DSM-5 dementia prevalent cases
  • Key population – Total DSM-IV dementia prevalent cases
  • Severity

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Ischemic Stroke – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute ischemic stroke (AIS) affects millions of individuals across G7 countries, according to Clarivate Epidemiology’s tracked lifetime and 12-month prevalent cohorts. As a time-critical…
Report
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Treatment – Current Treatment: Physician Insights – Neuromyelitis Optica Spectrum Disorder (US)
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Alzheimer’s Disease – Current Treatment – Current Treatment: Physician Insights – Alzheimer’s Disease (US)
Alzheimer’s disease (AD) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (DMT) is…